UBS Analysts Might've Found Another BioMarin Catalyst
August 21, 2015 at 09:41 AM EDT
In a report published Friday, UBS analyst Andrew Peters maintained a Buy rating on BioMarin Pharmaceutical Inc (NASDAQ: BMRN), with a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.